Abstract
Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients ≥2 yr with β-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of ≥3 mg Fe/g dry weight (dw) if baseline LIC was ≥10 mg Fe/g dw, or final LIC of 1-7 mg Fe/g dw for patients with baseline LIC of 2 to
| Original language | English |
|---|---|
| Pages (from-to) | 458-465 |
| Number of pages | 8 |
| Journal | European Journal of Haematology |
| Volume | 82 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2009 |
Fingerprint
Keywords
- β-thalassaemia
- Deferasirox
- Iron chelation
- Transfusional iron overload
ASJC Scopus subject areas
- Hematology
Cite this
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia : The ESCALATOR study. / Taher, Ali; El-Beshlawy, Amal; Elalfy, Mohsen S.; Al Zir, Kusai; Daar, Shahina; Habr, Dany; Kriemler-Krahn, Ulrike; Hmissi, Abdel; Al Jefri, Abdullah.
In: European Journal of Haematology, Vol. 82, No. 6, 06.2009, p. 458-465.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
T2 - The ESCALATOR study
AU - Taher, Ali
AU - El-Beshlawy, Amal
AU - Elalfy, Mohsen S.
AU - Al Zir, Kusai
AU - Daar, Shahina
AU - Habr, Dany
AU - Kriemler-Krahn, Ulrike
AU - Hmissi, Abdel
AU - Al Jefri, Abdullah
PY - 2009/6
Y1 - 2009/6
N2 - Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients ≥2 yr with β-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of ≥3 mg Fe/g dry weight (dw) if baseline LIC was ≥10 mg Fe/g dw, or final LIC of 1-7 mg Fe/g dw for patients with baseline LIC of 2 to
AB - Objective: Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. Methods: The prospective, open-label, 1-yr ESCALATOR study in the Middle East was designed to evaluate once-daily deferasirox in patients ≥2 yr with β-thalassaemia major and iron overload who were previously chelated with deferoxamine and/or deferiprone. Most patients began treatment with deferasirox 20 mg/kg/d; doses were adjusted in response to markers of over- or under-chelation. The primary endpoint was treatment success, defined as a reduction in liver iron concentration (LIC) of ≥3 mg Fe/g dry weight (dw) if baseline LIC was ≥10 mg Fe/g dw, or final LIC of 1-7 mg Fe/g dw for patients with baseline LIC of 2 to
KW - β-thalassaemia
KW - Deferasirox
KW - Iron chelation
KW - Transfusional iron overload
UR - http://www.scopus.com/inward/record.url?scp=65349152022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65349152022&partnerID=8YFLogxK
U2 - 10.1111/j.1600-0609.2009.01228.x
DO - 10.1111/j.1600-0609.2009.01228.x
M3 - Article
C2 - 19187278
AN - SCOPUS:65349152022
VL - 82
SP - 458
EP - 465
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 6
ER -